Waisenmedizin e.V. Freiburg and the Algerian Pasteur Institute (API) have signed an agreement of scientific cooperation (Convention particulière portant sur le projet “Contrôle de la Leishmaniose Cutanée en Algérie du 20 janvier 2017”). The Institutional Review Board (IRB) of the Algerian Pasteur Institute (API) has approved the non-interventional trial “LeiClean”, a combination of wound hygiene with cutaneous leishmaniasis lesion dressings using a filmogenic agent developed by WM e.V. Germany in Afghanistan (LeiClean) to be conducted in the forthcoming Leishmania season 2017/18. LeiClean includes the patients actively into their own treatment.